|Application ||FC, E|
|Purification||Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant|
|Immunogen||F(ab)2 fragment of Rituximab.|
|Shelf Life||18 months from date of despatch.|
|Target/Specificity||Rat anti-rituximab antibody, clone MB2A4, specifically recognizes the idiotypic determinants expressed by the rituximab chimeric monoclonal antibody. Rituximab is a therapeutic reagent directed against the human CD20 antigen expressed on the surface of B-cells.Rat anti-rituximab antibody, clone MB2A4, is specific for rituximab and does not recognize other CD20 antibodies. Clone MB2A4 has been used in ELISA assays to monitor the levels of rituximab in patient serum following therapy (Cragget al.2004andHampsonet al.2010). Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the anti-rituximab antibody to cell bound rituximab (Beumet al.2004).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Rituximab Antibody, clone MB2A4 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Cragg, M. S. et al. (2004) A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.Blood. 104:2540-2 2. Cragg, M.S. et al. (2004) Apparent modulation of CD20 by rituximab: an alternative explanation.Blood. 103 (10): 3989-90; author reply 3990-1. 3. Beum, P.V. et al. (2004) Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.J Immunol Methods. 294 (1-2): 37-42. 4. Hampson, G. et al. (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.J Immunol Methods. 360 (1-2): 30-8. 5. Blasco, H. et al. (2007) Evaluation of a peptide ELISA for the detection of rituximab in serum.J Immunol Methods.325: 127-39. 6. Daydé, D. et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.Blood. 113: 3765-72. 7. Aung, T. et al. (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.Proc Natl Acad Sci U S A. 108: 15336-41. 8. Schmidt, E. et al. (2009) Immunogenicity of rituximab in patients with severe pemphigus.Clin Immunol. 132: 334-41. 9. McDonald, V. et al. (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.J Thromb Haemost. 8: 1201-8. 10. Kagan, L. et al. (2012) Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats.Pharm Res. 29: 490-499 11. Kagan, L. and Mager, D.E. (2013) Mechanisms of subcutaneous absorption of rituximab in rats.Drug Metab Dispos. 41: 248-55. 12. Liu, X.F. et al. (2012) Validation of a Gyrolab™ assay for quantification of rituximab in human serum.J Pharmacol Toxicol Methods. 65: 107-14. 13. Kagan, L. et al. (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.Pharm Res. 31: 3265-73. 14. Blasco, H. et al. (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.Fundam Clin Pharmacol. 23: 601-8. 15. Pers, J.O. et al. (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.Arthritis Rheum. 56: 1464-77. 16. Vacher, P. et al. (2015) Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas.J Immunol. pii: 1402942. 17. Komori, M. et al. (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosisAnnals of Clinical and Translational Neurology. Feb 1. [Epub ahead of print]
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.
Request Quote Here